TRAX
First Tracks BiotherapeuticsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$606.78M
P/E Ratio
—
EPS
$-4.71
Beta
—
52W High
$26.80
52W Low
$11.30
50-Day MA
$19.10
200-Day MA
$19.10
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About First Tracks Biotherapeutics
First Tracks Biotherapeutics (Ticker: TRAX) is an innovative biotechnology company focused on advancing the development of targeted therapeutics for chronic diseases. With a strong emphasis on harnessing cutting-edge research and proprietary technology, TRAX aims to create transformative treatments that address unmet medical needs. The company is committed to improving patient outcomes through its novel drug candidates, which are designed to be effective and safe. As TRAX continues to progress through clinical trials, it seeks strategic partnerships to enhance its development pipeline and expand its market reach.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-139.61M |
| EBITDA | $-180.00M |
| Operating Margin | 0.00% |
| Return on Equity | -48.90% |
| Return on Assets | -29.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.38 |
| Price-to-Book | 2.31 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $34.89M |
| Float | $31.08M |
| % Insiders | 6.51% |
| % Institutions | 44.49% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Analyst Ratings
Consensus ($38.12 target)
3
Strong Buy4
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026